Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2010

View Archived Issues

Merck & Co.'s new GPR119 agonist lowers blood glucose in murine diabetes model

Angiochem's EPiC platform yields anticancer drugs with improved brain penetration

Renovis identifies novel P2X3 and P2X2/3 receptor antagonists

Janssen discloses novel NOP (ORL1) opioid receptor modulators

University of Central Florida claims new STAT3 inhibitors

Novartis presents novel antibacterial agents

Institute for OneWorld Health claims novel CFTR inhibitors

AD5-10: new option for treatment of ovarian cancer

Celgene and Agios collaborate to develop cancer metabolism programs

Advaxis begins phase II trial of ADXS11-001 in cervical dysplasia

Impax completes enrollment in phase III IPX-066 trial in Parkinson's disease

Genocea and U.S. military to collaborate on development of malaria vaccine

Mirabegron well tolerated and improves overactive bladder variables in large study

Studies on progesterone caproate for prevention of preterm birth

Rexahn reports phase IIa Serdaxin data in major depressive disorder

Impax amends copromotion agreement with Wyeth

D-Pharm receives agreement letter on SPA for phase III DP-b99 trial in acute ischemic stroke

Alexion's Soliris approved in Japan for paroxysmal nocturnal hemoglobinuria

PhytoMedical signs letter of intent with Medicilon for studies on brain cancer drug candidate

Updated phase I data presented on JI-101 in solid tumors

Diquas ophthalmic solution approved in Japan for dry eye treatment

Sandoz to acquire Oriel Therapeutics

Cell Therapeutics nears MAA submission for pixantrone in E.U.

FDA approves Tarceva as maintenance therapy for advanced non-small cell lung cancer

Cannasat Therapeutics becomes Cynapsus Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...